CDMO’s fill-finish line offers batch capacity of over 200,000 syringes.
Ajinomoto Bio-Pharma Services, a contract development and manufacturing organization (CDMO), noted that FDA has approved the company's high potency vial line to manufacture a commercial product.
When it comes to its US facilities, the CDMO has six fill-finish lines located in San Diego, including a new, multi-purpose line that has been designed to meet FDA and EMEA commercial compliance. It offers various configurations, including pre-filled syringes, cartridges, and vials. The high-speed process can move up to 22,000 syringes per hour through the line, with a batch capacity of over 200,000 syringes.
"Receiving FDA approval on our HPAPI [highly potent active pharmaceutical ingredients] fill line is an exciting milestone for our company, and couldn't have happened without the hard work, hours of preparation, diligence and support from the Aji Bio-Pharma team across our whole organization, comments Bert Barbosa, president & COO, Ajinomoto Bio Pharma Services, US. “… We are dedicated to providing high-quality drug process development and manufacturing services to biotechnology and pharmaceutical companies worldwide."
Newron, Myung In Pharm Form Partnership Centered Around Treating Schizophrenia in South Korea
January 14th 2025The license agreement will feature an upcoming Phase III trial and—depending on results—the development, manufacturing, and commercialization of evenamide as a potential treatment option.